InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
3
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+0.2%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Armitage James O, Director. Insider active across 1 company, notably Cardiff Oncology, Inc.. Cumulatively, 3 reports have been logged. Split: 3 buys · 0 sell. Total volume traded: €93k. History available since 19 March 2021. The latest transaction was filed on 16 September 2022 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations3 total
13,000 shares@ US$1.556421.8% of flowCommon StockSEC:0001628280-22-026245:0
Ideal exit: 13 Jun 2023 (T+270)
4,000 shares@ US$10.81780.032% mcap50.0% of flowCommon StockSEC:0001628280-21-011230:0
Ideal exit: 14 Dec 2021 (T+270)
4,000 shares@ US$10.817850.0% of flowCommon StockSEC:0001628280-21-011230
Ideal exit: 14 Dec 2021 (T+270)
3 of 3 declarations
About Armitage James O
James O. Armitage is a Board Member at Cardiff Oncology, Inc. He plays a key role in the governance of the company, influencing strategic decisions and contributing to its development.
